Navigation Links
Drug designer
Date:7/8/2011

Protease inhibitor drugs are one of the major weapons in the fight against HIV, the virus that causes AIDS, but their effectiveness is limited as the virus mutates and develops resistance to the drugs over time. Now a new tool has been developed to help predict the location of the mutations that lead to drug resistance.

First discovered in 1995, protease inhibitor drugs have dramatically reduced the number of AIDS deaths. Taken in combination with two other anti-HIV drugs, protease inhibitors work by halting the action of the protease enzyme, a protein produced by HIV that is necessary for replication of the virus. However, almost half of HIV patients who initially respond to treatment with protease inhibitors develop drug-resistance strains and stop responding to treatment within eight to 10 months.

Currently there are nine FDA approved protease inhibitors, and 21 most common drug-resistant mutations.

The main reason for the short-term effectiveness of the drug has to do with the evolution of the drug within the body, said the study's author, Yi Mao, a postdoctoral fellow at the National Institute for Mathematical and Biological Synthesis.

In the new study, published today in the journal BMC Structural Biology, Mao used a mathematical modeling technique called elastic network modeling to examine the physical properties and interactions of the proteins. The model reveals where mutations are occurring during the evolution of the HIV-virus proteins and how these mutations help the virus survive.

"With this kind of knowledge, better strategies for designing anti-HIV drugs could be developed," Mao said.

HIV kills the body's immune system cells, called CD4 cells. Once the number of CD4 cells dips below 200, an HIV patient enters the last stage of his or her disease: Acquired Immune Deficiency Syndrome, or AIDS. The first cases of AIDS were reported thirty years ago. Since then, more than 60 million people have been infected with HIV, and mor
'/>"/>

Contact: Catherine Crawley
ccrawley@nimbios.org
865-974-9350
National Institute for Mathematical and Biological Synthesis (NIMBioS)
Source:Eurekalert

Page: 1 2

Related biology news :

1. Consumers desire more genetic testing, but not designer babies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... Initial treatment for a brain infection caused by fungus could ... due to study by University of Liverpool scientists. , ... often fatal but are relatively neglected in medical research. ... Africa, Australasia and South East Asia and mainly affect people ... people a year. , The University research team has tested ...
(Date:4/24/2014)... Researchers from North Carolina State University and the University ... new ultrasound device that could help identify arterial plaque ... causing heart attack or stroke. , At issue is ... age. Some types of plaque are deemed "vulnerable," meaning ... artery wall and cause heart attack or stroke. , ...
(Date:4/24/2014)... home from Iraq and Afghanistan, post-traumatic stress disorder (PTSD) ... and the culture at-large. Estimates indicate that as many ... Afghanistan suffer from PTSD. New research from the University ... on how PTSD is linked to other diseases in ... has implications beyond the impact of the psychiatric disorder ...
Breaking Biology News(10 mins):Treatment for deadly yeast disease reduced to 3 days 2New ultrasound device may add in detecting risk for heart attack, stroke 2New study links inflammation in those with PTSD to changes in microRNA 2New study links inflammation in those with PTSD to changes in microRNA 3
... 2013 -- In January 2012, the United States Department ... make school lunches more nutritious, which included requiring schools ... either a fruit or vegetable with their purchased lunch. ... healthier lunches. In a new study scheduled for ...
... TAMPA, Florida (Feb. 21, 2013) Cardiovascular disease specialists at ... Research Institute affiliated with the University of South Florida announced ... testing a novel gene therapy for the treatment of heart ... regeneration of heart tissue by encouraging the body to deploy ...
... tissue and organ transplantation for diseases that are caused ... ethical discussions surrounding human embryonic stem cells, a lot ... (iPS cells). However, before this technique can be applied ... safety and efficacy of such iPS cells. VIB scientists ...
Cached Biology News:Smarter lunchrooms make lunch choices child's play 2New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site 2New therapy for heart failure may enhance body's stem cell response at cardiovascular injury site 3Cell therapy a little more concrete thanks to VIB research 2
(Date:1/15/2014)... , Jan. 15, 2014 TaiGen Biotechnology Company, Limited ... agreement with R-Pharm, a leading Russian pharmaceutical company, to ... Russian Federation , Turkey ... States (CIS). Nemonoxacin is a novel antibiotic for the treatment ...
(Date:1/14/2014)... Jan. 14, 2014  3D Communications, a leading provider of strategic communications ... and media events in the United States ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... Rockville, MD (PRWEB) January 14, 2014 ... dedicated to developing innovative information technology solutions for ... other health care stakeholders, announced today the signing ... the US Food and Drug Administration (FDA). ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2
... Amylin Pharmaceuticals,Inc. (Nasdaq: AMLN ) will webcast its ... on Monday, April 21, 2008 at 8:30 a.m. ET/5:30,a.m. ... will lead the call. On the same date pre-market, ... 2008., The call will be webcast live through ...
... 15 Excalibur, the new,international investment house launched ... of PIramed to Roche., (Photo: http://www.newscom.com/cgi-bin/prnh/20080415/301189 ... Roche for $185 million means a ,very substantial,cash ... fund created by Sir,Christopher five years ago., ...
... CALGARY, April 15 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,(TSX: ... by Dr. Anders,Kolb of the Nemours Center for ... for Pediatric Sarcomas" was,presented today at the American ... is being held in San Diego, California from,April ...
Cached Biology Technology:Amylin Pharmaceuticals to Webcast First Quarter Results 2Excalibur Celebrates PIramed Sale With 'Substantial Cash Return' to Investors 2Oncolytics Biotech Inc. Collaborators Present Reovirus Research for Pediatric Sarcomas at AACR Annual Meeting 2
... purified from egg white. The extinction coefficient , ... in 10 mM phosphate-buffered saline, pH ... sodium azide and 50% glycerol. Avidin (from egg ... is purified by molecular sieving and ...
Request Info...
Request Info...
... CELLection Dynabeads (4.5 m) coated with the ... EpCAM and DNase Releasing Buffer. For ... tumour cells directly from blood, bone marrow ... enriched from bone marrow. Enriched cells are ...
Biology Products: